Müller, N., Michen, S., Tietze, S., Töpfer, K., Schulte, A., Lamszus, K., . . . Temme, A. (2015). Engineering NK cells modified with an EGFRvIII-specific chimeric antigen receptor to overexpress CXCR4 improves immunotherapy of CXCL12/SDF-1α-secreting glioblastoma. J Immunother.
Chicago-tyylinen lähdeviittausMüller, Nadja, et al. "Engineering NK Cells Modified With an EGFRvIII-specific Chimeric Antigen Receptor to Overexpress CXCR4 Improves Immunotherapy of CXCL12/SDF-1α-secreting Glioblastoma." J Immunother 2015.
MLA-viiteMüller, Nadja, et al. "Engineering NK Cells Modified With an EGFRvIII-specific Chimeric Antigen Receptor to Overexpress CXCR4 Improves Immunotherapy of CXCL12/SDF-1α-secreting Glioblastoma." J Immunother 2015.
Varoitus: Nämä viitteet eivät aina ole täysin luotettavia.